All In MedTech

Device Trial Radar · NCT03334630

DiamondTemp™ Ablation System for the Treatment of Paroxysmal Atrial Fibrillation

A Randomized Controlled Clinical Evaluation of the DiamondTemp™ Ablation System for the Treatment of Paroxysmal Atrial Fibrillation

Last checked: Nov 20, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 482 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

482

Actual

Start

Nov 6, 2017

Primary completion

Nov 18, 2019

Study completion Dec 3, 2019

Sponsor

Lead sponsor
Medtronic Cardiac Ablation SolutionsPublic (MDT)
Sponsor type
Industry
First posted
Nov 7, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the DIAMOND-AF study is to establish the safety and effectiveness of the DiamondTemp System for the treatment of drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation in patients.

Conditions

  • Paroxysmal Atrial Fibrillation
  • Atrial Fibrillation

Interventions

  • DiamondTemp Ablation catheterDevice

    a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter

  • TactiCath Quartz Ablation catheterDevice

    a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Freedom From a Composite of Pre-specified Serious Adverse Events (SAEs)Time frame: Within 30-days or 6-months after index ablation procedure
  2. Effectiveness: Freedom From Documented Atrial Fibrillation(AF), Atrial Flutter(AFL) and Atrial Tachycardia(AT) Episodes Following the Blanking Period (3M Post-ablation) Through the End of the Effectiveness Evaluation Period (12M Post-ablation).Time frame: 3-12M (3-12 months) after index ablation procedure

Locations

23 sites in 5 countries. Site status is shown where the registry gives one.

  • Grandview Medical Center

    Birmingham, Alabama

  • University Of Alabama

    Birmingham, Alabama

  • Keck School Of Medicine

    Los Angeles, California

20 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.